For much of the past decade, the radiopharmaceutical industry has been defined by oncology. Prostate cancer, neuroendocrine tumors, breast cancer, glioblastoma. And the extraordinary success of precision oncology has fueled billions of dollars in investment across isotope production, radiopharmaceutical development, theranostics centers and manufacturing infrastructure.
Yet while much of the industry's attention remains focused on cancer, another market is quietly beginning to emerge—one that could ultimately rival oncology in both scale and long-term commercial opportunity. Neurological imaging.
As populations age and the prevalence of Alzheimer's disease, Parkinson's disease, Lewy body dementia, frontotemporal dementia, traumatic brain injury, epilepsy and other neurodegenerative disorders continues to rise, molecular imaging is becoming an increasingly important tool for understanding diseases that have historically been diagnosed largely through clinical observation. Nuclear medicine is beginning to provide something physicians have long lacked: the ability to visualize the biology of disease rather than simply its symptoms.
For the radiopharmaceutical industry, that represents an entirely new commercial frontier.
For decades, neurologists largely relied upon cognitive testing, MRI, CT imaging, neurological examinations and clinical progression to diagnose diseases such as Alzheimer's. While those tools remain critically important, they often identify disease only after irreversible neurological damage has already occurred. PET imaging is fundamentally changing that equation.
Amyloid imaging was the first major breakthrough. Radiotracers capable of identifying beta-amyloid plaque accumulation gave physicians an entirely new window into Alzheimer's disease, allowing pathology to be visualized years before traditional diagnostic certainty could be achieved. More recently, tau imaging has expanded clinicians' understanding of disease progression, while dopamine transporter imaging has become an essential tool for evaluating Parkinsonian syndromes. Researchers are now developing radiopharmaceuticals capable of imaging neuroinflammation, alpha-synuclein, synaptic density, microglial activation, mitochondrial dysfunction and numerous additional biological pathways associated with neurodegenerative disease.
This evolution mirrors what has already occurred in oncology.
Just as PSMA PET identifies patients most likely to benefit from targeted prostate cancer therapies, neurological PET imaging is becoming increasingly important for identifying appropriate patients, confirming diagnoses, monitoring disease progression, evaluating therapeutic response and supporting clinical trial enrollment. Precision neurology is beginning to follow the same path that precision oncology pioneered.
Several companies have already established important commercial positions.
GE HealthCaremarketsVizamyl, one of the first FDA-approved fluorine-18 PET imaging agents for detecting beta-amyloid plaques associated with Alzheimer's disease, while Lantheushas built a global presence aroundNeuraceq, another widely adopted amyloid PET radiopharmaceutical that continues expanding access to molecular brain imaging worldwide. Both products have become increasingly important as physicians seek greater diagnostic confidence for patients experiencing cognitive decline.
Eli Lilly helped establish the commercial importance of neurological imaging through Amyvid, one of the first FDA-approved amyloid PET agents, and later Tauvid, the first approved PET tracer targeting tau neurofibrillary tangles. More importantly, Lilly's disease-modifying Alzheimer's therapies have fundamentally changed the economics of molecular imaging. As treatments such as Kisunla (donanemab) become integrated into clinical practice, physicians increasingly require amyloid PET imaging to determine which patients are appropriate candidates before therapy begins. Imaging is no longer simply diagnostic, it is becoming essential to treatment selection.
Among the emerging innovators is CereMark Pharma, whose investigational imaging platform reflects where the field may be headed next. Rather than targeting a single pathological protein, the company's lead radiopharmaceutical has been developed to evaluate both beta-amyloid plaques and tau pathology within a single PET examination. If successful, that approach could provide clinicians with a more comprehensive understanding of disease progression while potentially improving patient selection for future neurological therapies. The company's work illustrates a broader industry trend toward increasingly sophisticated molecular imaging capable of revealing multiple aspects of disease biology simultaneously.
The innovation extends well beyond these organizations.
Companies including AC Immune, Biogen, Roche, AbbVie, Johnson & Johnson, Novartis and numerous emerging biotechnology firms are incorporating molecular imaging biomarkers into neuroscience drug development programs. Many clinical trials now depend on PET imaging to identify appropriate patients, demonstrate target engagement, monitor biological response and support regulatory endpoints. Molecular imaging has evolved from a research tool into an increasingly essential component of neurological drug development.
Perhaps the biggest commercial catalyst is not the imaging agents themselves but the therapies they support.
The arrival of disease-modifying Alzheimer's treatments is transforming clinical practice in much the same way that PSMA-targeted therapies transformed prostate cancer. Physicians can no longer rely solely on symptoms when selecting patients. They increasingly require biological confirmation before initiating treatment. Every new neurological therapy entering the market has the potential to create additional demand for PET imaging, radiopharmaceutical production, imaging centers, radiopharmacies and specialized interpretation.
The ripple effects extend throughout the nuclear medicine economy.
Growing neurological imaging volumes increase demand for cyclotron capacity, fluorine-18 production, PET/CT scanners, radiopharmacy networks, AI-assisted image analysis, quantitative imaging software and specialized molecular imaging centers. Companies building infrastructure for oncology may ultimately discover that neurology represents an equally attractive long-term growth opportunity.
Artificial intelligence is likely to accelerate that transition even further. Advanced quantitative software is already improving assessment of amyloid burden, tau distribution, regional brain metabolism and dopamine transporter imaging. As AI becomes integrated into neurological imaging workflows, physicians will gain increasingly sophisticated tools capable of measuring subtle biological changes over time, potentially allowing earlier diagnosis and more personalized treatment decisions.
Perhaps the most compelling aspect of this opportunity is the size of the addressable patient population.
Cancer remains one of medicine's largest markets, but neurodegenerative diseases affect tens of millions of people worldwide, with prevalence expected to increase dramatically as populations age. Alzheimer's disease alone represents one of the greatest healthcare challenges of the twenty-first century. If molecular imaging becomes a routine component of diagnosis, treatment selection and disease monitoring, imaging volumes could eventually rival some of today's largest oncology applications.
History suggests that every major therapeutic breakthrough creates new healthcare infrastructure. Precision oncology created theranostics centers. Cardiovascular medicine built catheterization laboratories. Biologic therapies expanded infusion centers.
Precision neurology now appears poised to begin building its own ecosystem. And as companies including CereMark Pharma, GE HealthCare, Life Molecular Imaging, Eli Lilly, AC Immune, Biogen, Roche and others continue advancing the science of molecular brain imaging, they are laying the foundation for what could become the next great expansion chapter in nuclear medicine—one in which earlier diagnosis, precision therapeutics and biologically targeted imaging fundamentally reshape the treatment of neurological disease.
